Advanced Cell Technology, Inc. (“ACT”; OTC:ACTC or the “Company”), a leader in the field of regenerative medicine, announced today third quarter financial results for the period ended September 30, 2013 and provided an update on their clinical and pre-clinical programs.
Highlights from the third quarter include:
•Received Data Safety Monitoring Board (“DSMB”) Approval to complete the third cohort, which entails finishing the enrollment and treatment of the remaining two patients, in each of the Company’s three ongoing clinical trials with the higher dosage of retinal pigment epithelial (“RPE”) cells derived from human embryonic stem cells (hESCs).
Help employers find you! Check out all the jobs and post your resume.
